<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589013</url>
  </required_header>
  <id_info>
    <org_study_id>2019_06</org_study_id>
    <secondary_id>2019-A03156-51</secondary_id>
    <nct_id>NCT04589013</nct_id>
  </id_info>
  <brief_title>Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer</brief_title>
  <acronym>PRINCE</acronym>
  <official_title>Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate a multiparametric test including 6 immunohistochemical markers&#xD;
      (PD-L1, CD8, FoxP3, PD1, CD163, CD15) to predict the cumulative incidence of death or&#xD;
      progression on treatment with pembrolizumab+first line chemotherapy in metastatic non-small&#xD;
      cell lung cancer, regardless of the PD-L1 status and in the absence of ALK, ROS1 or EGFR&#xD;
      alteration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The dependent variable will be the cumulative incidence of death or progression under immunotherapy + chemotherapy at 1 year.</measure>
    <time_frame>At 1 year</time_frame>
    <description>Progression will be evaluated by CT imaging every 12 weeks and then every 9 weeks according to RECIST 1.1.&#xD;
The independent variables will be the 6 immunohistochemical markers (PD-L1, CD8, FoxP3, PD1, CD163, CD15) evaluated prior to the first injection of pembrolizumab + chemotherapy from the diagnostic tissue material.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discrimination index (concordance index=C-statistics) of the multiparametric model and model including that of the PD-L1 test.</measure>
    <time_frame>At 1 year</time_frame>
    <description>Compare the discriminant power of the multiparametric model to that of the PD-L1 test alone.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients meeting the inclusion criteria will be selected in each of the centers (Lille CHU,&#xD;
        Lille Centre Oscar Lambret, Valenciennes Clinique Teissier, Roubaix CH) by the&#xD;
        onco-pneumologists and included in the study, after collecting the consent, at the start of&#xD;
        treatment with pembrolizumab + chemotherapy in first line.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years at time of diagnosis&#xD;
&#xD;
          -  Affiliation to a social insurance&#xD;
&#xD;
          -  Obtaining the patient's non opposition&#xD;
&#xD;
          -  Patients with non-small cell lung carcinoma, confirmed by anatomopathological,&#xD;
             metastatic or locally advanced unresectable, not eligible for local curative treatment&#xD;
&#xD;
          -  Cellular or tissue FFPE available&#xD;
&#xD;
          -  Indication of treatment with pembrolizumab + first line chemotherapy in&#xD;
             multidisciplinary consultation meeting&#xD;
&#xD;
          -  No mutation of the EGFR gene, no rearrangement of ALK and ROS,&#xD;
&#xD;
          -  At least one measurable tumor according to RECIST criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tissue or cellular FFPE not available&#xD;
&#xD;
          -  Systemic anti-neoplastic or immunotherapy previously received except neoadjuvant or&#xD;
             adjuvant treatment completed 6 months or more&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Humez</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Humez, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>sarah.humez@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clcc Oscar Lambret Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hop Calmette Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Victor Provot</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Teissier</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

